Tetavax

Tetavax

Manufacturer:

sanofi pasteur

Distributor:

DKSH
Concise Prescribing Info
Contents
Tetanus toxoid
Indications/Uses
Prevention of tetanus & in particular, post-exposure tetanus prophylaxis for recent wounds that have been contaminated w/ tetanus spores. Neonatal tetanus prohylaxis in non-immunised women either of childbearing age or pregnant; primary vaccination; booster inj.
Dosage/Direction for Use
Post-tetanus exposure prophylactic vaccine Patient not immunised or partially immunised Minor-clean wound: 1 dose. Major-clean or tetanus-prone wound: Human tetanus Ig 250 IU in 1 arm & tetanus toxoid 1 dose in the other arm. Tetanus prone/delayed or incomplete debridement: Human tetanus Ig 500 IU in 1 arm & tetanus toxoid 1 dose & antibiotic therapy in the other arm. Patient completely immunised (5-10 yr since last booster dose) Major-clean or tetanus prone around Tetanus toxoid 1 dose. Tetanus prone/delayed or incomplete debridement: Tetanus toxoid 1 dose & antibiotic therapy. Patient completely immunised (>10 yr since last booster dose) Minor-clean: Tetanus toxoid 1 dose. Major-clean or tetanus prone wound: Human tetanus Ig 250 IU in 1 arm & tetanus toxoid 1 dose in the other arm. Tetanus prone/delayed or incomplete debridement: Human tetanus Ig 500 IU in 1 arm & tetanus toxoid 1 dose & antibiotic therapy in the other arm. Neonatal tetanus prophylaxis Women of childbearing age & non-immunized pregnant women 2 successive inj at least 4 wk apart, preferably ≥90 days before birth. Primary immunization Adult 2 successive inj 1-2 mth apart followed by a booster dose 6-12 mth after the 2nd inj. Booster inj 1 dose 10 yr after primary immunisation & every 10 yr thereafter.
Contraindications
Hypersensitivity. Hypersensitivity reaction or neurological disorders caused by previous vaccination. Postponed vaccination in case of fever, acute disease or chronic progressive illness.
Special Precautions
Do not inject intravascularly & intradermal route. Immunosuppressive therapy/immunodeficiency condition; patients who had a complete primary vaccination or a booster dose in the previous 5 yr. Monitor for Guillain-Barre syndrome or brachial neuritis. Potential risk of apnoea & need for resp monitoring for 48-72 hr must be considered when administering the primary immunization series to very premature infants. Pregnancy & lactation.
Adverse Reactions
Lymphadenopathy; type I hypersensitivity reactions; cephalalgia, dizziness; hypotension; allergic-like symptoms eg, urticaria, generalized pruritus, or erythema; myalgia, arthralgia. Inj site reactions eg, pain, rash, induration or oedema; transient pyrexia; malaise.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07AM01 - tetanus toxoid ; Belongs to the class of tetanus bacterial vaccines.
Presentation/Packing
Form
Tetavax vaccine inj 0.5 mL
Packing/Price
(multidose vial) 10 dose x 1's; (pre-filled syringe) 0.5 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in